EANS-News: Oxygen Biotherapeutics Inc. / Study Shows Marked Neuroprotective Effects of Oxycyte® Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Research & Development/Biotechnology

Durham, NC (euro adhoc) - Press Release

Oxygen Biotherapeutics Inc.:

Study Shows Marked Neuroprotective Effects of Oxycyte®
Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury

DURHAM, NC, June 3, 2010 - Oxygen Biotherapeutics, Inc. (NASDAQ:
OXBT) today reported on the results of two University of Miami
Miller School of Medicine studies involving the Company´s
third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion.
Both study reports showed that Oxycyte® has a marked neuroprotective
effect in a rat model of spinal cord injury.

"Having proof-of-concept is a first step toward moving Oxycyte down
the spinal cord injury track. The positive results observed in both
studies warrant efforts to pursue partnerships to conduct clinical
studies of Oxycyte in spinal cord injury in the future," said Gerald
Klein, Chief Medical Officer for Oxygen Biotherapeutics.

The studies showed that histologically, Oxycyte improves the volume
of preserved neuronal tissue in the spinal cord following injury; a
favorable improvement in functional recovery, as assessed by
footprint analysis six weeks post treatment, has also been observed.

The study entitled "Possible Role of Hyperbaric Oxygen Therapy (HBO)
and Oxycyte After Spinal Cord Injury in Rats," will be part of the
poster sessions at the National Neurotrauma Symposium on June 14-16,
2010 at the Paris Hotel in Las Vegas. Results of the first study
entitled "Evaluation of the Neuroprotective and Behavioral Effects of
the Perfluorocarbon Oxycyte After Spinal Cord Injury (SCI) in the
Rat" were presented in September 2009 at the annual
National-International Neurotrauma Symposium by Dr. Ross Bullock,
University of Miami Miller School of Medicine. Both studies received
funding from Oxygen Biotherapeutics.

Oxycyte emulsion is a proprietary therapeutic oxygen carrier. It is a
perfluorocarbon emulsified with water and a surfactant that is
delivered intravenously.

According to statistics from various studies compiled by the National
Spinal Cord Injury Statistical Center in Birmingham, AL, an estimated
12,000 new cases of spinal cord injury occur each year in the United
States; and the number of people living in the United States with SCI
is estimated to be approximately 259,000 people. According to a study
initiated by the Christopher & Dana Reeve Foundation, approximately 6
million people worldwide are living with paralysis that is largely a
result of SCI.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic
products that efficiently deliver oxygen to tissues in the body. The
company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier and liquid ventilation product called Oxycyte that is
being formulated for both intravenous and topical delivery. In April,
the company launched its first cosmetic product, Dermacyte Oxygen
Concentrate. In addition, the company is focused on
perfluorocarbon-based oxygen carriers for use in traumatic brain
injury, decompression sickness, personal care, and topical wound
healing. More information is available at www.oxybiomed.com or
www.buydermacyte.com.

Caution Regarding Forward-Looking Statements.

This news release contains certain forward-looking statements by the
company that involve risks and uncertainties and reflect the
company's judgment as of the date of this release. These statements
include those referring to the plans for the expansion of the
Dermacyte product line and the timing of the introduction of those
new products. The forward looking statements are subject to a number
of risks and uncertainties including matters beyond the company´s
control that could lead to delays in the new product introductions
and customer acceptance of these new products and other risks and
uncertainties as described in our filings with the Securities and
Exchange Commission, including in the current report on Form 8-K on
May 4, 2010. Furthermore, there can be no assurance that such plans
will lead to meaningful sales of Dermacyte or generate any revenue
for the company. The company disclaims any intent or obligation to
update these forward-looking statements beyond the date of this
release. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

For further information please contact:

Ellen Corliss

Vice President, Corporate Communications

& Investor Relations

Oxygen Biotherapeutics, Inc

2530 Meridian Pkwy, 3rd floor

Durham, NC 27713

Direct Telephone: +1 919 806 4405

Direct Fax: +1 919 806 4417

Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: A0YD9Z
Börsen: New York / Nasdaq